iMedPub Journals http://www.imedpub.com

#### Journal of Cancer Epidemiology and Prevention

Vol. 5 No. 1:1

# A Nobel Multivariate Index for Cancer Risk Detection Based On the Serum Trace Elements: Metallo-Balance Method

### Abstract

**Objective:** There are increasing reports that many trace elements are playing important roles for biological forms. We used ICP-MS and developed a novel method for precise measurement of serum trace elements called "Metallo-Balance (MB) test" for the screening of cancer risk.

**Methods:** 463 patients with colorectal cancer (men:278; women 185), 277 patients with prostate cancer (men) and 429 patients with breast cancer (women) were collected in Kanagawa cancer center and Chiba cancer center, Japan, while 850 controls (men: 471; women: 379) w/o cancers were obtained from general population. Under IRB approved protocol serum samples were collected and subjected to ICP-MS analysis to measure 17 trace elements (Na, Mg, P, S, K, Ca, Fe, Zn, Cu, Se, Rb, Sr, As, Mo, Cs, Co, Ag). Cancer cases and controls were statistically measured the sensitivity, specificity and area under ROC curve (AUC).

**Results:** High sensitivity, specificity and AUC were confirmed by binominal logistic regression analysis. AUC for colorectal cancer (men) was 0.943 (95% CI, 0.920-0.966), 0.842 (0.801-0.882) for prostate cancer, 0.898 (0.861-0.935) for colorectal cancer (women), and 0.824 (0.783-0.865) for breast cancer. In particular, sensitivity of 80% or more in stages I and II can be considered effective as a cancer risk screening. Elements that became significant in connection with cancer were Mg, Co, Cu and Mo. Conversely, S, Zn and Rb were less relevant to cancer.

**Conclusion:** These results are considered to indicate that "the balance of trace elements in the blood is largely disrupted from the early stage and onset of cancer". MB test is a promising method for cancer detection and maybe risk assessment.

Keywords: Trace elements; Serum; Cancer risk; Screening; Multi-variate analysis

## Introduction

Development of cancer control programs has been an urgent task in many countries in the world, with many programs focusing on the introduction of screening methods aimed at early detection and treatment in specific regions. Various screening methods, such as palpation, imaging (X-ray, CT scan, MRI scan, PET scan, etc.), endoscopy, and xenodiagnoses (blood test, cytology, biopsy, etc.) have been introduced in many regions. However, accuracy and efficacy of these have not necessarily been sufficiently established [1]. For example, palpation is ocular inspection for which use is limited to external organs, breasts, colon, rectum, and stomach, while imaging requires expensive equipment and technicians and carries risks such as poor reading and radiation exposure. On the other hand, testing of body fluids, etc. has fewer burdens on the examinees and is considered to be easier to use during mass examination.

In Japan, screening using body fluids to identify blood tumor markers for unspecified sites (CA125, CA19-9, CEA, SCC etc.), PSA for prostate cancer, serum pepsinogen for stomach cancer, urine NMPP22 and CK8-18 for bladder cancer are implemented. Naoyuki Okamoto<sup>1+</sup>, Haruo Mikami<sup>2</sup>, Yohko Nakamura<sup>2</sup>, Miho Kusakabe<sup>2</sup>, Naohito Yamamoto<sup>3</sup>, Nobuhiro Takiguchi<sup>4</sup>, Yoshihiro Nabeya<sup>5</sup>, Hiroaki Soda<sup>6</sup>, Satoshi Fukasawa<sup>7</sup>, Takeshi Kishida<sup>8</sup>, Manabu Shiozawa<sup>9</sup>, Akira Yoshida<sup>10</sup>, Takuya Shimizu<sup>1</sup>, Shunsuke Fujimoto<sup>1</sup>, Mitsuhiro Ueda<sup>1</sup>, Seiichi Inagaki<sup>1</sup>, Yohei Miyagi<sup>11</sup>and Hiroki Nagase<sup>2</sup>

<sup>1</sup>Health Care Analysis Center, Renatech Co., Ltd. 4-19-15 Takamori, Isehara 259-1114, Japan

<sup>2</sup>Chiba Cancer Center Research Institute, 666-2 Nitona, Chuoh-ku, Chiba 260-8717, Japan

<sup>3</sup>Division of Breast Surgery, Chiba Cancer Center, 666-2 Nitona, Chuoh-ku, Chiba 260-8717, Japan

- <sup>4</sup>Division of Gastrointestinal Surgery, Chiba Cancer Center, 666-2 Nitona, Chuoh-ku, Chiba 260-8717, Japan
- <sup>5</sup>Division of Esophago-Gastrointestinal Surgery, Chiba Cancer Center, 666-2 Nitona, Chuoh-ku, Chiba 260-8717, Japan
- <sup>6</sup>Division of Gastrointestinal Surgery, Chiba Cancer Center, 666-2 Nitona, Chuoh-ku, Chiba 260-8717, Japan
- <sup>7</sup>Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona, Chuoh-ku, Chiba 260-8717, Japan
- <sup>8</sup>Department of Urology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama 241-8515, Japan
- <sup>9</sup>Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama 241-8515, Japan
- <sup>10</sup>Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama 241-8515, Japan
- <sup>11</sup>Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-ku, Yokohama 241-8515, Japan

#### \*Corresponding author:

Naoyuki Okamoto, Health Care Analysis Center, Renatech Co., Ltd. 4-19-15 Takamori, Isehara 259-1114 Japan, **Tel:** +81 949365061; Email: okamoto@renatech.net

Received date: December 26, 2019; Accepted date: January 16, 2020; Published date: January 23, 2020

**Citation:** Okamoto N, Mikami H, Nakamura Y, Kusakabe M, Yamamoto N, et al. (2020) A Nobel Multivariate Index for Cancer Risk Detection Based On the Serum Trace Elements: Metallo-Balance Method Cancer Epidemiology & Prevention Vol.5 No.1 DOI: 10.36648/cancer.5.1.4

**Copyright:** © 2020 Okamoto N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Furthermore, measurement of MicroRNA [2], nucleosomes [3], and apoAII [4] in the blood or saliva has recently been developed for cancer screening.

Trace elements are essential in a living body, but an excess or defficiency may inhibit normal vital reactions, leading to malfunction or disease. Many cases, for example anemia due to iron(Fe) deficiency [5], osteoporosis due to calcium(Ca) deficiency [6], Minamata disease due to excess mercury(Hg) [7], Keshan disease due to selenium(Se) deficiency [8], schizophrenia due to low zinc(Zn) [9], heart failure due to low magnesium(Mg), high phosphorus(P), and Ca [10], have been reported. It has also been reported that serum zinc is lower and calcium, copper, iron and magnesium are higher in breast cancer patients compared to the general population [11]. In addition, the Cu/Zn ratio has been reported to be higher in breast cancer patients [12] and ovarian cancer patients [13]. Similarly, several element concentrations in renal cell cancer [14], lung cancer [15], pancreatic cancer [16], colorectal cancer [17,18], oral cancer [19], prostate cancer [20] etc. have been reported to differ from healthy individuals. In this study, "cancer patients with abnormal concentrations of elements in the blood", as indicated in the above reports, were considered. A case-control study to compare blood samples from patients with colorectal cancer, breast cancer or prostate cancer, with those of and healthy normal persons was carried out in order to develop and implement a new index for use in screening for cancer risk.

## **Materials and Methods**


#### **Cases and controls**

463 patients with colorectal cancer (men: 278; women: 185), 277 patients with prostate cancer (men), 429 patients with breast cancer (women) who were treated at kanagawa cancer center and chiba cancer center in Japan from April 2005 to March 2015 were targeted in this study. After receiving an explanation from the primary physician, participants submitted a written informed consent form. After admission and diagnosis at the hospital and before the start of treatment, a 7 mL blood sample was drawn from the cubital vein in the morning fasting state. The sample was centrifuged at 3,000 rpm for 10 minutes with a preservative at room temperature and stored at -80°C until measurement of elements. The pathologic stage of each cancer after discharge was recorded and used.

The control group was formed from persons who received a standard examination in the region (mass examination) conducted by chiba cancer center each year. 850 people (men: 471; women: 379) who had not developed any cancer during 15-year follow-up period as part of the Japan Multi-Institutional Collaborative Cohort Study: J-MICC study [21] and who provided consent for the provision of a blood sample for cancer study were selected. Blood (7 mL) was drawn at the baseline for an independent study in the Chiba region and the same process was performed and samples were stored at -80°C until measurement. Absence of cancer was confirmed in this control group at the end of 2015 by record linkage with the Chiba Population based Cancer Registry.

#### Study design

The flow of this study is shown in **Figure 1**. Ages in the targeted cases and the control group were between 30 to 79 years and were matched as close as possible. Subjects were then randomly divided into two groups by sex and by cancer sites, with one group for training data and the other for validation data. Training and validation data consisted of colorectal cancer (men) 139 and 139, colorectal cancer (women) 93 and 92, breast cancer 214 and 215, prostate cancer 139 and 138. For the control group, 236 and 235 men, 190 and 189 women, respectively.



Binomial logistic regression analysis of the training data by sex and by site was performed. After determining the best indicator, indicative power of the validation data of the subject and control groups was examined. However, there were no persons in the control group who corresponded to prostate cancer patients under the age of 49 years, so 218 persons from the control group were analyzed.

#### **Reagents and instruments**

Reagents: 61% nitric acid solution: Kanto Chemical Co., Ltd.,

30% Hydrogen peroxide solution: Kanto Chemical Co., Ltd.,

XSTC-622B (Mixed standard solution for ICP-MS): SPEX,

Standard solution (Na, Mg, P, S, K, Ca, Be, Te) for atomic absorption analysis: Kanto Chemical Co., Ltd.,

ICP-MS metal standard solution (Y, Rh) for ICP-MS: AccuStandard

**Equipment:** All devices used for measurement of trace elements, such as sample storage bins, sampling bins and micropipette tips, were made of polypropylene. All containers were washed with ultra-pure water (18.00 M  $\Omega$ •CM or more), then 500  $\mu$ L of 61% nitric acid was added to the containers and heated overnight. The containers were then washed again with ultra-pure water, filled with 10% nitric acid, and heated for 2 nights. The containers were then washed with ultra-pure water. The measuring instrument used ICP-MS (Agilent 7800).

#### **Experimental operations**

Sample pretreatment: 50 µL of the blood sample was weighed

in a pluggable polypropylene container, 125  $\mu L$  of 61% nitric acid solution was added and 25  $\mu L$  of 30% hydrogen peroxide water was mixed and heated at 70 °C for 16 hours.

**Preparation of calibration curve:** XSTC-622B was appropriately diluted with a 3% nitric acid solution, and calibration curves of iron (Fe), copper (Cu), zinc (Zn), arsenic (As), strontium (Sr), cobalt (Co), rubidium (Rb), selenium (Se), molybdenum (Mo), cesium (Cs), and silver (Ag) were prepared. In addition, single element standard solutions were mixed and appropriately diluted with a 3% nitric acid solution to prepare calibration curves of sodium (Na), magnesium (Mg), phosphorus (P), sulfur (S), potassium (K) and calcium (Ca). The correlation coefficient was 0.9998 or more for any of the 17 elements.

**Analysis conditions of ICP-MS:** Apparatus conditions were high frequency output 1550 W, plasma gas flow rate 15 L/min, nebulizer gas flow rate 1.05 L/min, and auxiliary gas flow rate L/min. Samples were introduced into the apparatus by suction using a peristaltic pump. As internal standard elements, beryllium (Be), yttrium (Y), Rhodium (Rh) and tellurium (Te) were added to 50, 5, 1 and 50 µg/L, respectively. Under the above conditions, 17 elements including Na (ppm), Mg (ppm), P (ppm), S (ppm), K (ppm), Ca (ppm), Fe (ppb), Co (ppb), Cu (ppb), Zn (ppb), As (ppb), Se (ppb), Rb (ppb), Sr (ppb), Mo (ppb), Ag (ppb) and Cs (ppb) were measured by ICP-MS.

#### age-class (integer value obtained by dividing age by 10) and 17 logarithmically converted elements. For each of the 18 measurement items, Student's t-test was used to determine any difference between target cases and the control group. Furthermore, binomial logistic regression analysis was performed using multivariate analysis according to all 18 items. Sensitivity, specificity, area under the ROC (Receiver Operating Characteristic) Curve (AUC) [22,23] were calculated. Excel Analysis (BellCurve, Japan) and SPSS Ver.24 (IBM, USA) were used for all processing.

### Results

For the training data and validation data according to the number of cases by age-class, the number of patients with cancer by stage and affected site is shown in **Table 1**. No differences in age and stage distribution were observed.

Mean and Standard Deviation (SD) of the measurements of training data of the 17 elements and age-class divided by cancer site, between the target cases and control group are shown in **Table2a and 2b** (gray area is less than 5% with significant difference). For colorectal cancer (men), Na, Mg, K, Ca, Fe, Co, Cu and Zn were significantly higher and S, Fe, Rb, Mo and Cs were lower compared to the control group. For prostate cancer, Na, Ca, Fe, Co, Cu, As and Se were significantly higher and Rb and Cs were significantly lower. For colorectal cancer (women), Na, Mg, Ca, Co, Cu, Zn and Ag were significantly higher and Rb and Cs were lower element. For breast cancer, Na, Mg, P, S, Ca, Fe, Co, Cu, Zn, Se and Sr were significantly higher and Rb and Cs

#### Statistical processing

Data items used for analysis included 18 items according to

Cancer site	Item	Class		Training data			Validation data			
			Control	Case	Total	Control	Case	Total		
		30-39	5	3	8	5	3	8		
		40-49	13	12	25	12	11	23		
	Age	50-59	45	Case         Total           3         8           12         25           31         76           57         155           36         111           4         -           33         -           39         -           139         375           14         59           59         157           66         141           0         -           23         -           71         -           34         -	76	45	31	76		
		60-69	98	57	155	98	58	156		
Colorectal		70-79	75	36	111	75	36	111		
cancer (male)		0	-	4	-	-	3	-		
		I	-	33	-	-	28	-		
	Stage	П	-	39	-	-	Case 3 11 31 58 36 3 3	-		
		Ш	-	44	-	-		-		
		IV	-	18	-	-		-		
	Тс	otal	236	139	375	235	139	374		
		50-59	45	14	59	45	15	60		
	Age	60-69	98	59	157	98	57	155		
		70-79	75	66	141	75	66	141		
		0	-	0	-	-	Case         3         11         31         58         36         3         28         36         52         20         139         15         57         66         2         27         52         40         16	-		
Prostate cancer		I	-	23	-	-		-		
	Stage	II	-	71	-	-		-		
			-	34	-	-	40	-		
		IV	-	10	-	-	16	-		
	Тс	otal	218	139	357	218	Case 3 11 31 58 36 3 28 36 52 20 139 15 57 66 2 27 52 40 16	356		

Vol. 5 No. 1:1

		30-39	7	2	9	8	2	10
		40-49	28	5	33	33         28         4           75         51         22           95         59         37           71         43         27           -         -         5           -         -         24           -         -         24           -         -         24           -         -         24           -         -         28           -         -         28           -         -         11           283         189         92           36         8         29           91         28         62           69         51         18           130         59         71           78         43         35           -         -         23           -         -         23           -         -         25           -         -         2           -         -         2           -         -         2           -         -         2           -         -         2           -		32
	Age	Age50-59532275512260-69583795593770-79442771432770-79442771432770-79442771432770-7944277143271-277.052411-277.02424111207.024241111377.02828111157.011111111909328318992111190932831892940-49286391286250-59531669511860-695872130597170-79443478433511-21235tageII-30111-2125111-225	73					
		60-69	60-695837955937170-79442771432710-4511-272411-2024111-37-24111-37-281111-37-112811-37-1111129328318992130-3972936829140-492863912862150-595316695118160-6958721305971170-79443478433511-211411-30231	96				
Colorectal		70-79	44	27	71	51       22         59       37         43       27         -       5         -       24         -       24         -       28         -       11         189       92         8       29         28       62         51       18         59       71         43       35         -       14         -       23         -       25         -       25         -       2	70	
Cancer(female)		0	-	4	-	-	4         22         37         27         5         24         24         24         24         28         11         92         29         62         18         71         35         14         23         25         0	-
		I	-	27	-	-		-
	Stage	II	-	20	-	-	24	-
		III	-	37	-	-	4 22 37 27 5 24 24 24 28 11 92 29 62 18 71 35 14 23 25 2 0	-
		IV	-	5	-	-	11	-
	Total		190	93	283	189	92	281
		30-39	7	29	36	8	29	37
		40-49	28	7         29         36           28         63         91	28	62	90	
	Age	50-59	53	16	69	51	4         22         37         27         5         24         24         24         28         11         92         29         62         18         71         35         14         23         25         0	69
		60-69	58	72	130	59		130
Breast cancer		70-79	44	34	78	43	35	78
Breast cancer		0	-	12	-	-	14	-
		I	-	21	-	-	22 37 27 5 24 24 24 28 11 92 29 62 18 71 35 62 18 71 35 14 23 25 2 2 0	-
	Stage		-	30	-		25	-
		III	-	2	-	-	18         71         35         14         23         25         2         0	-
		IV	-	0	-	-		-
	То	otal	190	214	404	189	215	404

 Table 2a: Results to Student's t-test between case and control of training data by cancer site (Male).

		Co	olorectal cano	er		Prostate cancer					
Item	Control (n=236)		Case (n=139)			Control (n=218)		Case (n=138)			
	mean	SD	mean	SD	p value	mean	SD	mean	SD	p value	
Age-class	5.953	0.96	5.799	0.994	0.1374	6.138	0.731	6.377	0.664	0.002	
In(Na)	8.048	0.035	8.072	0.024	<0.001	8.05	0.034	8.058	0.027	0.0209	
ln(Mg)	2.948	0.079	2.997	0.077	<0.001	2.949	0.078	2.949	0.079	0.9448	
In(P)	4.7	0.118	4.691	0.132	0.5176	4.695	0.119	4.699	0.124	0.7864	
ln(S)	6.986	0.078	6.956	0.083	<0.001	6.985	0.078	6.99	0.074	0.6246	
ln(K)	5.088	0.088	5.123	0.086	<0.001	5.09	0.088	5.107	0.078	0.0727	
ln(Ca)	4.478	0,074	4.501	0.053	0.0016	4.481	0.073	4.516	0.051	< 0.001	
ln(Fe)	6.807	0.372	6.698	0.667	0.0433	6.809	0.373	6.985	0.345	< 0.001	
ln(Co)	-2.407	0.374	-1.876	0.635	<0.001	-2.402	0.38	-2.274	0.282	<0.001	
ln(Cu)	6.663	0.173	6.819	0.2	<0.001	6.665	0.169	6.753	0.201	< 0.001	
ln(Zn)	6.586	0.181	6.667	0.197	<0.001	6.58	0.181	6.582	0.148	0.8908	
ln(As)	0.95	0.594	0.998	0.708	0.4836	0.989	0.573	1.129	0.573	0.0256	
ln(Se)	4.918	0.143	4.909	0.139	0.5337	4.915	0.143	4.972	0.17	<0.001	
ln(Rb)	5.109	0.186	5.013	0.191	<0.001	5.099	0.185	4.989	0.204	<0.001	
ln(Sr)	3.417	0.314	3.412	0.296	0.8776	3.421	0.319	3.478	0.3	0.0957	
ln(Mo)	0.324	0.551	0.13	0.47	<0.001	0.349	0.551	0.474	0.464	0.0281	
In(Ag)	-1.422	0.865	-1.255	0.801	0.0645	-1.437	0.879	-1.456	0.993	0.857	
ln(Cs)	-0.349	0.28	-0.434	0.302	0.0059	-0.356	0.279	-0.468	0.297	< 0.001	

		Co	olorectal cano	er	Breast cancer					
ltem	Control (n=190)		Case (n=93)			Control (n=190)		Case (n=214)		
	mean	SD	mean	SD	p value	mean	SD	mean	SD	p value
Age-class	5.547	1.11	5.887	0.965	0.0137	5.547	1.11	5.222	1.314	0.0091
In(Na)	8.052	0.036	8.072	0.027	<0.001	8.052	0.036	8.069	0.022	< 0.001
ln(Mg)	2.971	0.076	3.009	0.083	<0.001	2.971	0.076	2.987	0.073	0.0419
In(P)	4.787	0.11	4.77	0.127	0.2535	4.787	0.11	4.812	0.112	0.0248
ln(S)	6.981	0.068	6.945	0.086	<0.001	6.981	0.068	7.021	0.065	<0.001
ln(K)	5.055	0.099	5.068	0.085	0.2581	5.055	0.099	5.069	0.118	0.1967
ln(Ca)	4.475	0.081	4.498	0.054	0.013	4.475	0.081	4.53	0.043	< 0.001
ln(Fe)	6.61	0.427	6.63	0.541	0.7441	6.61	0.427	6.769	0.465	< 0.001
ln(Co)	-2.105	0.671	-1.788	0.63	<0.001	-2.105	0.671	-1.896	0.662	0.0023
ln(Cu)	6.748	0.163	6.907	0.252	<0.001	6.748	0.163	6.801	0.174	0.0016
ln(Zn)	6.583	0.19	6.658	0.165	0.0013	6.583	0.19	6.635	0.149	0.0033
ln(As)	0.712	0.661	0.839	0.732	0.1424	0.712	0.661	0.765	0.692	0.44
ln(Se)	4.89	0.139	4.904	0.163	0.4435	4.89	0.139	4.946	0.138	<0.001
ln(Rb)	5.051	0.18	4.917	0.305	<0.001	5.051	0.18	4.972	0.192	<0.001
ln(Sr)	3.339	0.269	3.387	0.28	0.17	3.339	0.269	3.401	0.31	0.0381
ln(Mo)	0.216	0.478	0.186	0.471	0.6081	0.216	0.478	0.177	0.406	0.3853
In(Ag)	-1.412	0.85	-1.145	0.893	0.0154	-1.412	0.85	-1.422	0.838	0.8461
In(Cs)	-0.384	0.307	-0.589	0.319	<0.001	-0.384	0.307	-0.5	0.285	<0.001

Table 2b: Results to Student's t-test between case and control of training data by cancer site (Female).

 Table 3: Partial regression coefficient and significance by binominal logistic regression analysis.

ltem	Colorectal	Ca. (Male)	Prosta	ate Ca.	Colorectal C	Ca. (Female)	Breast Ca.		
	Partial regression coefficient	p value	Partial regression coefficient	p value	Partial regression coefficient	p value	Partial regression coefficient	p value	
Age-class	-0.6347	0.0039	0.2877	0.1702	-0.0555	0.7885	-0.4455	<0.001	
In(Na)	30.4559	<0.001	-6.7256	0.2242	22.2788	0.0095	5.5959	0.3471	
ln(Mg)	6.3226	0.0208	2.6142	0.1928	4.5762	0.1001	1.0818	0.5768	
ln(P)	-1.4564	0.3927	-1.9335	0.114	1.3537	0.4873	-0.9784	0.4676	
ln(S)	-20.8789	<0.001	-13.2833	<0.001	-22.3568	<0.001	-3.7657	0.2022	
ln(K)	5.5054	0.0658	3.6056	0.122	3.5334	0.2214	1.0895	0.4306	
ln(Ca)	14.5858	0.0137	19.1967	<0.001	9.2026	0.083	19.0774	< 0.001	
ln(Fe)	0.2338	0.6396	1.595	<0.001	0.4622	0.308	0.8731	0.0072	
ln(Co)	2.8334	<0.001	1.5398	<0.001	0.8677	0.0052	0.8257	<0.001	
ln(Cu)	3.608	0.0013	2.444	0.0028	3.2998	0.0028	0.7888	0.3574	
ln(Zn)	3.2695	0.0073	-0.6342	0.469	2.6192	0.0101	0.6533	0.4236	
ln(As)	0.4994	0.1163	0.0449	0.8578	-0.0079	0.9785	0.0624	0.7761	
ln(Se)	-1.2302	0.5075	2.3001	0.0682	1.5885	0.2781	0.9217	0.3999	
ln(Rb)	-6.6253	<0.001	-4.3976	<0.001	-4.8747	0.002	-4.006	<0.001	
ln(Sr)	-0.9881	0.108	-0.5453	0.2595	-0.2144	0.7561	-0.505	0.2847	
ln(Mo)	-1.6054	<0.001	0.0364	0.9029	-0.1996	0.6124	-3.382	0.2233	
In(Ag)	0.0187	0.937	0.0722	0.6478	0.3136	0.1562	-0.2353	0.1313	
ln(Cs)	0.2258	0.7716	-0.5048	0.4229	-0.8379	0.2934	-0.4571	0.438	

were significantly lower. Six elements were significantly different for all affected sites-Na, Ca, Co, Cu, Rb and Cs, suggesting that these elements are strongly related to the development and progress of cancer. In the univariate analysis, some elements showed significant difference between the target cases and the control group. However, identification of the affected cancer site by only one element was not possible. Therefore, age-class measurements based on training data were added to the 17 elements as the analysis data, and multivariate analysis using binomial logistic regression analysis was performed.

Results of the ROC curve and AUC by binominal logistic regression analysis are shown in **Figure 2**. In colorectal cancer (men), AUC and 95% coincident interval (CI) were 0.943 and 0.920-0.966, 0.842 and 0.801-0.882 in prostate cancer, 0.898 and 0.861-0.935 in colorectal cancer (women), and 0.824 and 0.783-0.865 in breast cancer, respectively. From these results, differentiation between target cases and the control group by binomial logistic regression analysis was possible using the 17 elements plus age-class, and four indicator functions could be calculated from 4 cancer sites as indicators for each tumor to ensure validity by validation analysis using the validation data.

Partial regression coefficient and statistical significance of four indicators obtained by the binomial logistic regression analysis are shown in **Table 3**. In colorectal cancer (men), Na, Mg, Ca, Co, Cu, and Zn were strongly associated with cancer, and S, Rb, and Mo were strongly associated with non-cancer. In prostate cancer, Ca, Fe, Co, and Cu were highly associated with cancer, and S and Rb were strongly associated with non-cancer. In colorectal cancer (women), Na, Co, Cu, and Zn were highly associated with cancer, and S and Rb were strongly associated with non-cancer. In breast cancer, Ca, Fe, Co, and others were highly associated with cancer, and Rb was strongly associated with non-cancer.

In order to verify the four indicators, analysis using the validation data was performed. For cancer, sensitivity was calculated by stage, and for the control group, specificity was calculated. Results are shown in **Figure 3**. For colorectal cancer (men), specificity was 83.4% (196/235), sensitivities for stage 0, stage I, stage II, stage III, and IV were 100.0% (3/3), 75% (21/28) 77.8% (28/36), 80.8% (42/52), and 100.0 (20/20) respectively. For prostate cancer, specificity was 67, 4% (147/218), sensitivities were 100.0% (2/2), 81.5% (22/27), 69.2% (36/52), 72.5% (29/40), 87.5% (14/16), respectively. For colorectal cancer (women), specificity was 89.4% (169/189), sensitivities were 60.0% (3/5), 54.2% (13/24), 83.3% (20/24), 82.1% (23/28), 81.8% (9/11) respectively. In breast cancer, specificity was 67.7% (128/189), sensitivities were 81.8% (18/22), 82.7% (67/81), 75.6% (59/78), and 64.3 (9/14) respectively. There were no stage IV breast cancer patients.

### Discussion

Minerals, which contain trace elements, along with proteins, carbohydrates, fats, vitamins and water, compose the six basic nutrients essential for human and animal life. When an element is not sufficiently supplied a deficiency occurs, and when in excess, poisoning symptoms occur. In addition, some elements which are not classified as essential elements of the body are still considered necessary for enzyme activity, especially for substance metabolism and intercellular communication. When trace elements are deficient or in excess, metabolic balance of the body, etc. is lost, and symptoms specific to each element appear. In addition, the composition of trace elements is said to change due to the onset of a disease, poor physical condition or an immune system disorder, and homeostasis (homeostasis) breaks down. Various reports have suggested a link between the biological significance of each element and disease, such as reports on pollution-related illness, anemia [5], type II diabetes [24], cardiovascular disease [25], age-related macular degeneration [26], schizophrenia [9], Alzheimer's disease [27], and a wide range of other health conditions. Many reports have suggested a correlation between trace elements and malignant neoplasms [28]. From this, the possibility of estimating the risk of cancer incidence was examined in this study using a case-control method to compare trace element concentrations in the blood of cancer patients and general healthy persons. In addition to serum and plasma, hair [29,30], saliva [31], nails [32,33], urine [34] have been used as samples for trace element measurement, but blood, which is easy to collect and has standardized handling methods, was used in this study.

Detection methods include ICP-OES (Inductively-Coupled Plasma Optical Emission Spectroscopy), atomic absorption spectrometry (AAS), X-Ray Fluorescence analysis (X-Ray Fluorescence analysis) (XRF) etc., but the ICP-MS (Inductively coupled plasma mass spectrometry) method was used due to its simplicity and because quantitative reliability of the measurement results could be ensured. In order to measure trace elements of a biological sample by ICP-MS, pretreatment in order to dissolve the mixture of proteins, fats, etc. into a homogeneous solution is needed. In general, nitric acid is used and the sample is dissolved by microwaves, and then the solution is used as a reference [35]. However, when microwaves were used, elution (contamination) of trace elements from the container due to high temperature decomposition was confirmed, so a new pretreatment method which did not require a high temperature was developed. (See Methods)


According to analysis of each of the 17 measured elements plus age-class, a significant difference in element concentrations in cancer patients at all cancer sites targeted (**Tables 2a and 2b**) was observed, suggesting a change in the balance of trace elements in the blood, and indicating carcinogenesis.


Na, Mg, Ca, Co, Cu, Zn were observed in high concentrations and were common to three or more cancer sites. Conversely, S, Fe, Rb and Cs were observed in low concentrations in cancer (**Tables 2a and 2b**). Na, Mg, Cu, and Zn are thought to be involved in division, differentiation, and metastasis of cancer cells through actions related to ion channels, ion pumps, and Na-K-ATPase [36]. Trace elements in the blood of cancer patients differ from those in healthy persons. For example, a decrease in Sulphur is thought to occur as large amounts are used as a component in amino acids and proteins in cancer cells and as a catalyst in the metabolism of sugars and fats. According to Al-Awadi, et al., when human cancer cells were transplanted into nude mice, serum cystine and homocysteine decreased [37]. Szabo, et al. reported that H2S derived from colon cancer cells by cystathionine- $\beta$ -synthase

(CBS) stimulated cell activity (bioenergetics), cell proliferation and angiogenesis [38]. Similarly, other elements are suspected to be involved in cancer cell proliferation by activating energy metabolism and sugar/lipid metabolism through catalysis. In particular, it is reported that many trace elements are involved in angiogenesis [39-41], which is essential for the growth of cancer cells. Analysis of these mechanisms is thought to lead to the development of research in a new field named "Metallomics".

From the univariate analysis results, it is hypothesized that each trace element is independently involved in cancer development. However, mutual influence may also occur since trace elements may exhibit antagonizing or opposing action. Therefore, analysis using multivariate analysis was carried out to further clarify the distinction between cancer patients and the general public.

The ROC curve and AUC by multivariate discriminant analysis using 18 items of 17 elements plus age class are shown in Figure 2. AUC for colorectal cancer (men) was 0.943 (95% CI, 0.920-0.966), 0.842 (0.801-0.882) for prostate cancer, 0.898 (0.861-0.935) for colorectal cancer (women), and 0.824 (0.783-0.865) for breast cancer. With regarding to current FOBT screening methods for colorectal cancer, Dodou et al. [42] calculated AUC=0.802 by 23 meta-analysis reports, and for digital mammography screening methods for breast cancer [43]. According to data analysis, AUC=0.79, and for prostate cancer screening with PSA, Louie et al. [44] reported that AUC=0.71 from six reliable reported meta-analyses. AUC in this report was determined to be high at all cancer sites, and the results of discriminant analysis using trace elements in blood were significant as a new screening method. Four binomial logistic regression equations derived from multivariate analysis using training data were found to be useful in distinguishing between early stage and advanced stage cancer by inputting validation data (Figure 3). In particular, sensitivity of 80% or more in stages I and II can be considered effective as a cancer risk screening. These results are considered to indicate that "the balance of trace elements in the blood is largely disrupted from the early stage and onset of cancer".





**Figure 3:** Predicting value (%) when substituting validation data into discriminant derived from training data analysis.

To date, several studies have used multivariate analysis (discriminant analysis or logistic regression analysis) to consider the relationship between trace elements in blood and cancer. Nakayama et al. [45] has shown that multivariate discriminant analysis of metallothionein, Cu and Zn levels in serum of patients with chronic hepatitis, cirrhosis and liver cancer can be classified with 80%-90% sensitivity. Wu et al. [46] examined 13 elements in the blood of 25 breast cancer patients, 43 benign breast cancer patients, and 26 healthy subjects. Co, Ni, and Al were significantly higher concentrations in breast cancer patients. It is reported that Cd, Mn, Fe, Cr and Zn were identified by logistic regression analysis using the stepwise method, and discrimination was possible with a sensitivity of 96% or more. Yasuda et al. [30] performed logistic regression analysis and multiple linear regression analysis using 24 elements from hair of 124 solid cancer patients and 86 healthy persons. As a result, AUC=0. 918 and I, As, Zn, Fe, Na, Se, K and Mn were identified.

## Conclusion

These studies were conducted in order to compare cancer patients with healthy persons and to identify elements related to cancer development, and no mention regarding an imbalance of trace elements is mentioned. In this study, all measured elements were used as data for identification, and "the risk of cancer" could be estimated by the difference in the balance. From these results, risk of experiencing colorectal cancer and prostate cancer in men and colorectal cancer and breast cancer in women can be estimated with high probability based on one blood sample.

Currently, research aimed at risk diagnosis for lifestyle related diseases including cancer in other areas are underway, and progress in research for practical use has been made. By placing the results of this research in practical use, risk assessment of lifestyle-related diseases (referred to as Metallo-Balance) is possible. Through annual blood collection to monitor serum trace elements, health support for many persons is possible. In addition, improvement in risk management is expected to increase public awareness and wellness.

## Acknowledgements

This study was conducted together with Chiba Cancer Center, Kanagawa Cancer Center and RENATECH Co., Ltd. by the support of the Ministry of Economy, Trade, and Industry of Japan (Accepted number 2831412036). For blood specimen of controls, we gained support from the Platform of Supporting Cohort Study and Biospecimen Analysis, J-MICC Research, (Kenji Wakai, Chief investigator, Professor of Preventive Medicine, Nagoya University Graduate School of Medicine) of the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

### Grants

The support of the Ministry of Economy, Trade, and Industry of Japan (Accepted number 2831412036)

## COI

The authors declare no conflicts of interest associated with this manuscript.

## References

- PDQ<sup>®</sup> Screening and Prevention Editorial Board. PDQ Cancer Screening Overview. Bethesda, MD: National Cancer Institute (US). 2019.
- 2 Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M (2010) Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 6: 78-95.
- 3 Ito H, Hasegawa K, Hasegawa Y, Nishimaki T, Hosomichi K, et al. (2015) Silver nanoscale hexagonal column chips for detecting cellfree dna and circulating nucleosomes in cancer patients. Sci Rep 5: 10455.
- 4 Honda K, Kobayashi M, Okusaka T, Rinaudo JA, Huang Y, et al. (2015) Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-All isoforms. Sci Rep 5:15921.
- 5 Spivak JL (2002) Iron and the anemia of chronic disease. Oncology 16: 25-33.
- 6 Emsrud KE, Duong T, Cauley JA, Heaney RP, WOLF RL, et al. (2000) Low fractional calcium absorption increases the risk for hip fracture in women with low calcium. Ann Interm Med 132: 345-353.
- 7 Kurland LT, Faro SN and Siedler H. Minamata Disease. 1961. 76: 671-2.
- 8 Chen J (2012) An original discovery: Selenium deficiency and keshan disease (an endemic heart disease). Asia Pac J Clin Nutr 21: 320-326.
- 9 Cal L, Chen T, Yang J, Zhou K (2015) Serum trace element differences between schizophrenia patients and controls in the han chinese population. Sci Rep 5:15013.
- 10 Lutsey PL, Alomso A, Michos ED, Loehr LR, Astor BC, et al. (2014) Serum magnesium, phosphorus, and calcium are associated with risk of incident heart failure: The atherosclerosis risk in communities (ARIC) study. Am J Cin Nutr 100: 756-764.
- 11 Pavithra V, Sathisha TG, Kasturi K, Mallika DS, Amos SJ, et al. (2015) Serum levels of metal ions in female patients with breast cancer. J Clinic and Diag Reserch 9: BC25-BC27.
- 12 Gupta SK, Shukla VK, Vaidya MP, Roy SK, Gupta S (1991) Serum trace elements and Cu/Zn ratio in breast cancer patients. J Surg Oncol 46:178-181.
- 13 Gal D, Lischinsky S, friedman M, Zinder O (1989) Prediction of the presence of ovarian cancer at surgery by an immunochemical panel: CA125 and zinc ratio. Gynecol Oncol 35: 246-250.
- 14 Pirinççi N, Geçit I, Gunes M, Kaba M, Tamk S, et al. (2013) Levels of serum trace elements in renal cell carcinoma cases. Asian Pacific J Cancer Prev 14: 499-502.
- 15 Diez M, Arroyo M, Cerdan FJ, Munoz M, Martin MA, et al. (1989) Serum and tissue trace metal levels in lung cancer. Oncology 46: 230-234.
- 16 Manousos O, Trichopoulos D, Koutselinis A, Papadimitriou C, Polychronopoulou A, et al. (1981) Epidemiologic characteristics and trace elements in pancreatic cancer in Greece. Cancer Detect Prev 4: 439-442.
- 17 AL Fari NA, Ahmad D (2011) Distribution of trace elements like calcium, copper, iron and zinc in serum samples of colon cancer: A case control study. J of King Saud Univ 23: 337-340.

- 18 Khoshdel Z, Naghibalhossaini F, Abdollahi K, Shojaei S, Moradi M, et al. (2016) Serum copper and zinc levels among Iranian cololectal cancer patients. Bio Trace Elem Res 170: 294-299.
- 19 Hosthor SB, Mahesh P, Priya SA, Sharada P, Jyotsna M, et al. (2014) Quantitative analysis of serum levels of trace elements in patients with oral submucous fibrosis and oral squamous cell carcinoma: A randomized cross-sectional study. J Oral Maxillofac Pathol 18: 46-51.
- 20 Dudas CN, Mitra B, Kandegedara A, Chen D, Schmitt S, et al. (2012) Association of metals and proteasome activity in erythrocytes of prostate cancer patients and controls. Bio Trace Elen Res 149: 5-9.
- 21 Hamajima N, J-MICC (2007) Study Group: The japan multiinstitutional collaborative cohort study (J-MICC Study) to detect gene-environment interactions for cancer. Asian Pac J Cancer Preve 8: 317-323.
- 22 Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36.
- 23 Hajian-Tilaki K (2013) Receiver operating characteristic (roc) curve analysis for medical diagnostic test evaluation. Caspian J Intern Med 4: 627-635.
- 24 Zhang H, Yan C, Yang Z, Zhang W, Niu Y, et al. (2017) Alterations of serum trace elements in patients with type 2 diabetes. J Trace Elem Med Biol 40: 91-96.
- 25 Aoki Y, Brody DJ, Flegal KM, Fakhouri TH, Axelrad DA, et al. (2016) Blood lead and other metal biomarkers as risk factors for cardiovascular disease mortality. Medicine (Baltimore) 95: 2223.
- 26 Park SJ, Lee JH, Woo SJ, Kang SW, Park KH (2015) Epidemiologic survey committee of korean ophthalmologic society : Five heavy metallic elements and age-related macular degeneration: Korean national health and nutrition examination survey, 2008-2011. Ophthalmology 122: 129-137.
- 27 Koseoglu E, Koseoglu R, Kendirci M, Saraymen R, Saraymen B (2017) Trace metal concentrations in hair and nails from Alzheimer's disease patients: Relations with clinical severity. J Trace Elem Med Biol 39: 124-128.
- 28 Fukuda H, Ebara M, Yamada H, Arimoto M, Okabe S, et al. (2004) Trace elemets and cancer. JMAJ 47: 391-395.
- 29 Czerny B, Krupka K, Ozarowski M, Mrozikiewicz AJ (2014) Screening of trace elements in hair of the female population with different types of cancers in wielkopolska region of poland. Scientific World Journal 2014:953181.
- 30 Yasuda H, Yoshida K, Segawa M, Tokuda R, Tsutsui T, et al. (2009) Metallomics study using hair mineral analysis and multiple logistic regression analysis: Relationship between cancer and minerals. Environ Health Prev Med 14: 261-266.
- 31 Kode MA, Karjodkar FR (2013) Estimation of the serum and the salivary trace elements in osmf patients. J Clin Diagn Res 7: 1215-1218.
- 32 Amaral AF, Porta M, Silverman DT, Milne RL, Kogevinas M, et al. (2012) Pancreatic cancer risk and levels of trace elements. Gut 61: 1583-1588.
- 33 Steevens J, van den Brandt PA, Goldbohm RA, Schouten LJ (2010) Selenium status and the risk of esophageal and gastric cancer subtypes: The netherlands cohort study. Gastroenterology 138: 1704-1713.
- 34 Lin CN, Wang LH, Shen KH (2009) Determining urinary trace elements (Cu, Zn, Pb, As, and Se) in patients with bladder cancer. J Clin Lab

Anal 23: 192-195.

- 35 Harrington JM, Young DJ, Essader AS, Summer SJ, Levine KE (2014) Analysis of human serum and whole blood for mineral content by ICP-MS and ICP-OES: Development of a mineralomics method. Biol Trance Ele Res 160: 132-142.
- 36 Litan A, Langhans SA (2015) Cancer as a channelopathy: Ion channels and pumps in tumor development and progression. Front Cell Neurosci 9:86.
- 37 Al-Awadi F, Yang M, Tan Y, Han Q, Li S, et al. (2008) Human tumor growth in nude mice is associated with decreased plasma cysteine and homocysteine. Anticancer Res 28: 2541-2544.
- 38 Szabo C, Coletta C, Chao C, Modis K, Szczesny B, et al. (2013) Tumorderived hydrogen sulfide, produced by cystathionine-β-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. Pros Natl Acad Sci USA 110: 12474-12479.
- 39 Saghiri MA, Asatourian A, Orangi J, Sorenson CM, et al. (2015) Function role of inorganic trace elements in angiogenesis-Part I: N, Fe, Se, P, Au, and Ca. Crit Rev Oncol Hematol 96: 129-142.
- 40 Saghiri MA, Asatourian A, Orangi J, Sorenson CM, Sheibani N (2015) Function role of inorganic trace elements in angiogenesis-Part II: Cr, Si, Zn, Cu, and S. Crit Rev Oncol Hematol 96: 143-155.

- 41 Saghiri MA, Orangi J, Asatourian A, Sorenson CM, Sheibani N (2016) Function role of inorganic trace elements in angiogenesis part III: (Ti, Li, Ce, As, Hg, Va, Nb and Pb). Crit Rev Oncol Hematol 98: 290-301.
- 42 Dodou D, de Winter JC (2015) Agreement between self-reported and registered colorectal cancer screening: A meta-analysis. Eur J Cancer Care (Engl) 24: 286-298.
- 43 Pisano ED, Hendrick RE, Yaffe MJ, Baum JK, Acharyya S, et al. (2008) Diagnostic accuracy of digital versus film mammography: Exploratory analysis of selected population subgroups in DMIST. Radiology 246: 376-383.
- 44 Louie KS, Seigneurin A, Cathcart P, Sasieni P (2015) Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann Oncol 26: 848-864.
- 45 Nakayama A, Fukuda H, Ebara M, Hamasaki H, Nakajima K, et al. (2002) A new diagnostic method for chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma based on serum metallothionein, copper, and zinc levels. Biol Pharm Bull 25: 426-431.
- 46 Wu HD1, Chou SY, Chen DR, Kuo HW (2006) Differentiation of serum levels of trace elements in normal and malignant breast patients. Biol Trace Elem Res 113: 9-18.